SLAMF3 Antibody
| Code | Size | Price |
|---|
| PSI-6251-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-6251-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
SLAMF3 Antibody: hly9, mLY9, CD229, SLAMF3, T-lymphocyte surface antigen Ly-9, Cell surface molecule Ly-9
Application Note:
SLAMF3 antibody can be used for detection of SLAMF3 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunocytochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
SLAMF3 Antibody: The signaling lymphocyte-activation molecule family member 3 (SLAMF3), also known as LY9, is a cell surface receptor that is expressed on T and B lymphocytes and belongs to the CD150/SLAMF1 receptor family. SLAMF3 was identified through a yeast two-hybrid screening in which SLAMF3 bound to the X-linked lymphoproliferative disease gene product SAP, suggesting that in activated T cells, SLAMF3 signaling can be triggered SAP. Its expression on the cell surface appears to be regulated via its interaction with the clathrin-associated adaptor complex 2 (AP-2). Despite its similarity to SLAMF1 in structure and interactions with SAP, SLAMF3-deficient mice do not exhibit phenotypic characteristics associated with SLAMF1- and SAP-deficient mice, suggesting that SLAMF3 plays other roles in T cell activation.
Background References:
- Sayos J, Martin M, Chen A, et al. Cell surface receptors Ly-9 and CD84 recruit the X-linked lymphoproliferative disease gene product SAP. Blood 2001; 97:3867-74.
- Del Valle JM, Engel P, and Martin M. The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2). J. Biol. Chem. 2003; 278:17430-7.
- Graham DB, Bell MP, McCausland MM, et al. Ly9 (CD229)-deficient mice exhibit T cell defects yet do not share several phenotypic characteristics associated with SLAM- and SAP-deficient mice. J. Immunol. 2006; 176:291-300.
Buffer:
SLAMF3 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
SLAMF3 antibody was raised against an 18 amino acid synthetic peptide near the carboxy terminus of human SLAMF3.
The immunogen is located within amino acids 520 - 570 of SLAMF3.
The immunogen is located within amino acids 520 - 570 of SLAMF3.
NCBI Gene ID #:
4063
NCBI Official Name:
lymphocyte antigen 9
NCBI Official Symbol:
LY9
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_1769
Protein GI Number:
55925578
Purification:
SLAMF3 Antibody is affinity chromatography purified via peptide column.
Research Area:
Immunology
SPECIFICITY:
At least three isoforms of SLAMF3 are known to exist. SLAMF3 antibody is predicted to not cross-react with other SLAM protein family members.
Swissprot #:
Q9HBG7
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | SLAMF3 Peptide | PSI-6251P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|